Impact of airborne particulate matter exposure on hospital admission for Alzheimer's disease and the attributable economic burden: evidence from a time-series study in Sichuan, China DOI Creative Commons
Xi Yang,

Wanyanhan Jiang,

Gao Xi

et al.

Environmental Sciences Europe, Journal Year: 2024, Volume and Issue: 36(1)

Published: Jan. 10, 2024

Abstract Background Alzheimer's disease (AD) and other forms of dementia are the seventh leading cause death. Studies discern inclusion air pollution among modifiable risk factors for dementia, while limited studies China. This study aims to examine short-term association between airborne particulate matter (PM) hospitalizations AD, including economic costs in Methods A total 4975 cases AD patients hospitalized from 2017 2019, were collected nine city 411 medical institutions Sichuan Province, Data on pollutants such as PM 2.5 , 10 NO 2 obtained 183 quality monitoring stations Province. time series-generalized additive model was used estimate exposure (lag1–lag7 moving average lag01–lag07) hospital admissions (HAs), stratified by gender, age, season. Results Positive found HAs AD. The greatest effect number inpatients single-day lag1 (PM :1.034 (95% confidence interval (CI) 1.011, 1.058)). also significant two-pollutant model. In period, 16.48% attributed PM. attributable US$ 2.56 million, 2.25 million direct 0.31 indirect costs. Conclusions suggests that may increase Province result associated

Language: Английский

Perspectives on Aging and Quality of Life DOI Open Access
Shinichi Noto

Healthcare, Journal Year: 2023, Volume and Issue: 11(15), P. 2131 - 2131

Published: July 26, 2023

The aging of the world's population and health problems accompanying it are becoming increasingly severe. Healthcare policies in developed countries focus on how to prevent treat diseases associated with maintain quality life. Typical age-related include deafness, cataracts, osteoarthritis, chronic obstructive pulmonary disease, diabetes mellitus, dementia. Although mechanisms by which these develop differ, they all caused accumulation molecular cellular damage over time. In addition, can cause a decline physical mental functions ability perform activities daily living, as well loss roles society sense fulfillment Therefore, there is need for treatment measures accurately grasp This review aims introduce areas representative papers expected be contributed special issue "Aging Quality Life".

Language: Английский

Citations

47
Artificial Intelligence for Cognitive Health Assessment: State-of-the-Art, Open Challenges and Future Directions DOI Creative Commons
Abdul Rehman Javed, Ayesha Saadia, Huma Mughal

et al.

Cognitive Computation, Journal Year: 2023, Volume and Issue: 15(6), P. 1767 - 1812

Published: June 24, 2023

Abstract The subjectivity and inaccuracy of in-clinic Cognitive Health Assessments (CHA) have led many researchers to explore ways automate the process make it more objective facilitate needs healthcare industry. Artificial Intelligence (AI) machine learning (ML) emerged as most promising approaches CHA process. In this paper, we background delve into extensive research recently undertaken in domain provide a comprehensive survey state-of-the-art. particular, careful selection significant works published literature is reviewed elaborate range enabling technologies AI/ML techniques used for CHA, including conventional supervised unsupervised learning, deep reinforcement natural language processing, image processing techniques. Furthermore, an overview various means data acquisition benchmark datasets. Finally, discuss open issues challenges using AI ML along with some possible solutions. summary, paper presents tools, lists methods provides technological advancements, usage issues, domain. We hope first-of-its-kind will significantly contribute identifying gaps complex rapidly evolving interdisciplinary mental health field.

Language: Английский

Citations

37
Burden of Common Neurologic Diseases in Asian Countries, 1990–2019: An Analysis for the Global Burden of Disease Study 2019 DOI Creative Commons
Yue Wang, Jingjing Liang, Yuting Fang

et al.

Neurology, Journal Year: 2023, Volume and Issue: 100(21)

Published: April 4, 2023

Based on the Global Burden of Diseases, Injuries, and Risk Factors (GBD) study, neurologic disorders are a major cause morbidity mortality worldwide. However, there has been no comprehensive assessment in Asia. Data from GBD 1990-2019 study were investigated to provide new details for Asia.The burden common Asia was calculated 1990 2019 as incidence, prevalence, deaths, disability-adjusted life-years (DALYs). Thirteen analyzed. presented totals by sex, age, year, location, risk factors, sociodemographic index (SDI) shown counts rates.In 2019, most burdensome absolute number DALYs stroke (98.8 million, 95% uncertainty interval [UI] 91.0-107.0), migraine (24.6 UI 3.4-56.4), Alzheimer disease (AD) other dementias (13.5 5.9-29.8). From deaths caused combined (deaths 60.7% 17.6%) increased, but age-standardized rates 34.1% 36.3%) decreased. The peaked among individuals aged 65-74 years higher male than female individuals; moreover, this varied considerably across Asian subregions countries. Risk-attributable accounted 86.9%, 28.5%, 11.1% stroke, AD dementias, multiple sclerosis, respectively. SDI associated with both communicable neurological disorders. In terms crude rate, value, prevalence lower all metrics disorders.Neurologic leading second may likely increase growth aging population. Urgent measures needed prevention, treatment, rehabilitation, support services regionally nationally.

Language: Английский

Citations

35
Economic Burden of Alzheimer’s Disease: A Systematic Review DOI Creative Commons
Lyn Xuan Tay, Siew Chin Ong,

Lynn Jia Tay

et al.

Value in Health Regional Issues, Journal Year: 2023, Volume and Issue: 40, P. 1 - 12

Published: Nov. 14, 2023

Language: Английский

Citations

31
Eye-tracking paradigms for the assessment of mild cognitive impairment: a systematic review DOI Creative Commons
Alexandra Wolf, Kornkanok Tripanpitak,

Satoshi Umeda

et al.

Frontiers in Psychology, Journal Year: 2023, Volume and Issue: 14

Published: July 20, 2023

Mild cognitive impairment (MCI), representing the ‘transitional zone’ between normal cognition and dementia, has become a novel topic in clinical research. Although early detection is crucial, it remains logistically challenging at same time. While traditional pen-and-paper tests require in-depth training to ensure standardized administration accurate interpretation of findings, significant technological advancements are leading development procedures for Alzheimer’s disease (AD) facilitating diagnostic process. Some protocols, however, show limitations that hamper their widespread adoption. Concerns about social economic implications increasing incidence AD underline need reliable, non-invasive, cost-effective, timely scoring methodologies. For instance, modern studies report oculomotor impairments among patients with MCI, who perform poorly visual paired-comparison tasks by ascribing less attentional resources stimuli. To accelerate Global Action Plan on Public Health Response Dementia 2017–2025, this work provides an overview research saccadic exploratory eye-movement deficits older adults MCI. The review protocol was drafted based Preferred Reporting Items Systematic Reviews Meta-Analyses guidelines. Electronic databases were systematically searched identify peer-reviewed articles published 2017 2022 examined processing MCI reported gaze parameters as potential biomarkers. Moreover, following contemporary trend remote healthcare technologies, we reviewed implemented non-commercial eye-tracking instrumentation order detect information population. Based gathered literature, eye-tracking-based paradigms may ameliorate screening assessments contribute detection. However, translate findings pertaining abnormal behavior into applications, imperative conduct longitudinal investigations both laboratory-based ecologically valid settings.

Language: Английский

Citations

24
Advances in blood biomarkers for Alzheimer disease (AD): A review DOI Creative Commons

Araya Dimtsu Assfaw,

Suzanne E. Schindler, John C. Morris

et al.

The Kaohsiung Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 40(8), P. 692 - 698

Published: June 18, 2024

Abstract Alzheimer disease (AD) and Disease Related Dementias (AD/ADRD) are growing public health challenges globally affecting millions of older adults, necessitating concerted efforts to advance our understanding management these conditions. AD is a progressive neurodegenerative disorder characterized pathologically by amyloid plaques tau neurofibrillary tangles that the primary cause dementia in individuals. Early accurate diagnosis crucial for effective intervention treatment but has proven challenging accomplish. Although testing brain pathology with cerebrospinal fluid (CSF) or positron emission tomography (PET) been available over 2 decades, most patients never underwent this because inaccessibility, high out‐of‐pocket costs, perceived risks, lack AD‐specific treatments. However, recent years, rapid progress made developing blood biomarkers AD/ADRD. Consequently, have emerged as promising tools non‐invasive cost‐effective diagnosis, prognosis, monitoring progression. This review presents evolving landscape AD/ADRD explores their potential applications clinical practice early detection, therapeutic interventions. It covers advances biomarkers, including beta (Aβ) peptides, protein, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP). also discusses diagnostic prognostic utility while addressing associated limitations. Future research directions rapidly field proposed.

Language: Английский

Citations

9
Research progress of PROTACs for neurodegenerative diseases therapy DOI

Zhifang Cai,

Zunhua Yang,

Huilan Li

et al.

Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 147, P. 107386 - 107386

Published: April 18, 2024

Language: Английский

Citations

8
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review DOI Creative Commons

Radhakrishna Reddi Sree,

Manjunath Kalyan,

Nikhilesh Anand

et al.

ACS Omega, Journal Year: 2025, Volume and Issue: 10(6), P. 5148 - 5171

Published: Feb. 3, 2025

Alzheimer's disease (AD) is an aging-related irreversible neurodegenerative affecting mostly the elderly population. The main pathological features of AD are extracellular Aβ plaques generated by APP cleavage through amyloidogenic pathway, intracellular neurofibrillary tangles (NFT) resulting from hyperphosphorylated tau proteins, and cholinergic neurodegeneration. However, actual causes unknown, but several studies suggest hereditary mutations in PSEN1 -2, APOE4, APP, TAU genes major perpetrators. In order to understand etiology pathogenesis AD, various hypotheses proposed. These include following hypotheses: amyloid accumulation, tauopathy, inflammation, oxidative stress, mitochondrial dysfunction, glutamate/excitotoxicity, deficiency, gut dysbiosis. Currently approved therapeutic interventions donepezil, galantamine, rivastigmine, which cholinesterase inhibitors (ChEIs), memantine, N-methyl-d-aspartate (NMDA) antagonist. treatment strategies focus on only symptomatic management attenuating symptoms not regeneration neurons or clearance Tau. This review focuses pathophysiology, novel targets, disease-altering treatments such as α-secretase modulators, active immunotherapy, passive natural antioxidant products, nanomaterials, antiamyloid therapy, aggregation inhibitors, transplantation fecal microbiota stem cells, microtubule stabilizers that clinical trials still under investigation.

Language: Английский

Citations

1
Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules DOI
Nassima Oumata,

Kui Lu,

Yuou Teng

et al.

European Journal of Medicinal Chemistry, Journal Year: 2022, Volume and Issue: 240, P. 114578 - 114578

Published: July 9, 2022

Language: Английский

Citations

29
Exploring Patient Perspectives: A Structured Interview Study on Deep Brain Stimulation as a Novel Treatment Approach for Mild Cognitive Impairment DOI
Pooja Venkatesh, Bradley Lega, Michael Rubin

et al.

AJOB Neuroscience, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 12

Published: Dec. 31, 2024

Limited treatments for Mild Cognitive Impairment (MCI) highlight the need to explore innovations including Deep Brain Stimulation (DBS), with patient perspectives key ethical protocol development.

Language: Английский

Citations

6